Podcast: FDA's Tezak Looks Ahead On Next-Gen Sequencing Regs
This article was originally published in The Gray Sheet
Executive Summary
FDA's Zivana Tezak was pleasantly surprised at the high level of complexity that stakeholders brought to a recent meeting on using curated databases to support next generation sequencing cancer tests. The conversations are a good jumping off point for the agency as it plans to hold back-to-back workshops on NGS in November, she said in a podcast interview with "The Gray Sheet."